Cover Image
市場調查報告書

EpiCast Report:克隆氏症 (CD) - 流行病學預測

EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 570409
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:克隆氏症 (CD) - 流行病學預測 EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026
出版日期: 2017年10月01日 內容資訊: 英文 47 Pages
簡介

本報告提供全球主要7個國家的克隆氏症 (CD) 調查分析,疾病的背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢 (成果)
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
  • 克隆氏症 (CD)的流行病學預測
    • 克隆氏症 (CD) 與確診的發病數量
    • 克隆氏症 (CD) 和確診的患者數
    • 克隆氏症 (CD) 和確診的患者數 (各年齡)
    • 克隆氏症 (CD) 和確診的患者數 (性別)
    • 克隆氏症 (CD) 和確診的患者數:各重症度
    • 作為克隆氏症 (CD) 和確診的患者數 (有自體免疫疾病合併症)
  • 克隆氏症 (CD)的替代流行病學預測
    • 克隆氏症 (CD) 確診的發病數量
    • 克隆氏症 (CD) 和確診的患者數
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER160-17

Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon). The disease course of CD is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of the parts of the bowel.

Our epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 at an Annual Growth Rate (AGR) of 0.53%. The US will have the highest number of diagnosed incident cases of CD in both 2016 and 2026 at 44,886 and 47,477, respectively.

Our epidemiologists forecast that the diagnosed prevalent cases of CD in the 7MM will increase from 1,621,866 in 2016 to 1,961,224 in 2026 at an AGR of 2.09%. The US will have the highest number of diagnosed prevalent cases of CD in both 2016 and 2026; however, France will have the highest AGR at 4.04%.

The report "EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and global and historical trends for CD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of CD in these markets. The diagnosed prevalent cases of CD are further segmented by sex and age in these markets. The diagnosed prevalent cases are further segmented by severity (mild to moderate, moderate to severe, and severe to fulminant) and by comorbid autoimmune diseases (psoriasis, ankylosing spondylitis, and pyodermagangrenosum).

Furthermore, an alternate forecast of diagnosed incident and diagnosed prevalent cases of CD is provided for markets where there was insufficient data to trend in the main forecast, to estimate the patient size if trending was applied. For incident cases the alternate forecast includes the US and 5EU (France, Germany, Italy, Spain, and UK), and for prevalent cases the alternate forecast includes Germany, Italy, Spain, and the UK.

Scope

  • The Crohn's Disease (CD) EpiCast Report provides an overview of the risk factors and global trends for CD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of CD in these markets. The diagnosed prevalent cases of CD are further segmented by sex and age in these markets. The diagnosed prevalent cases are further segmented by severity (mild to moderate, moderate to severe, and severe to fulminant) and by comorbid autoimmune diseases (psoriasis, ankylosing spondylitis, and pyoderma gangrenosum). Furthermore, an alternate forecast of diagnosed incident and diagnosed prevalent cases of CD is provided for markets where there was insufficient data to trend in the main forecast, to estimate the patient size if trending was applied.
  • The CD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The CD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CD market.
  • Quantify patient populations in the global CD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CD therapeutics in each of the markets covered.
  • Understand magnitude of CD population by disease severity and comorbid autoimmune diseases.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Crohn's Disease: Executive Summary 4

  • 2.1 Related Reports 6
  • 2.2 Upcoming Reports 7

3 Epidemiology 8

  • 3.1 Disease Background 8
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
    • 3.3.1 US 11
    • 3.3.2 5EU 12
    • 3.3.3 Japan 12
  • 3.4 Forecast Methodology 13
    • 3.4.1 Sources 13
    • 3.4.2 Forecast Assumptions and Methods 16
  • 3.5 Epidemiological Forecast for Crohn's Disease (2016-2026) 25
    • 3.5.1 Diagnosed Incident Cases of Crohn's Disease 25
    • 3.5.2 Diagnosed Prevalent Cases of Crohn's Disease 26
    • 3.5.3 Age-Specific Diagnosed Prevalent Cases of Crohn's Disease 27
    • 3.5.4 Sex-Specific Diagnosed Prevalent Cases of Crohn's Disease 28
    • 3.5.5 Diagnosed Prevalent Cases of Crohn's Disease by Severity 29
    • 3.5.6 Diagnosed Prevalent Cases of Crohn's Disease with Comorbid Autoimmune Diseases 30
  • 3.6 Alternate Epidemiological Forecast for Crohn's Disease (2016-2026) 31
    • 3.6.1 Diagnosed Incident Cases of Crohn's Disease 31
    • 3.6.2 Diagnosed Prevalent Cases of Crohn's Disease 32
  • 3.7 Discussion 33
    • 3.7.1 Epidemiological Forecast Insight 33
    • 3.7.2 Limitations of Analysis 34
    • 3.7.3 Strengths of Analysis 35

4 Appendix 36

  • 4.1 Bibliography 36
  • 4.2 Primary Research - KOLs Interviewed for this Report 42
  • 4.3 Primary Research - Prescriber Survey 44
  • 4.4 About the Authors 45
    • 4.4.1 Epidemiologist 45
    • 4.4.2 Reviewers 45
    • 4.4.3 Global Director of Therapy Analysis and Epidemiology 46
    • 4.4.4 Global Head and EVP of Healthcare Operations and Strategy 46
  • 4.5 About GlobalData 47
  • 4.6 Contact Us 47
  • 4.7 Disclaimer 47

List of Tables

  • Table 1: Risk Factors and Comorbidities for Crohn's Disease 9
  • Table 2: 7MM, Diagnosed Incident Cases of CD, All Ages, Both Sexes, Select Years 2016-2026 26
  • Table 3: 7MM, Diagnosed Prevalent Cases of CD, Men and Women, All Ages, Select Years 2016-2026 27
  • Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 44

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of CD, Both Sexes, All Ages, 2016 and 2026 5
  • Figure 2: 7MM, Diagnosed Prevalent Cases of CD, Both Sexes, All Ages, 2016 and 2026 6
  • Figure 3: 7MM, Age-Adjusted Diagnosed Prevalence of CD (%), Men, All Ages, 2006 to 2026 10
  • Figure 4: 7MM, Age-Adjusted Diagnosed Prevalence (%) of CD, Women, All Ages, 2006-2026 11
  • Figure 5: Sources Used and Not Used, Diagnosed Incident Cases of CD 14
  • Figure 6: Sources Used and Not Used, Diagnosed Prevalent Cases of CD 15
  • Figure 7: Sources Used, Diagnosed Prevalent Cases of CD with Comorbid Autoimmune Diseases 16
  • Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of CD, Both Sexes, 2016 28
  • Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of CD, All Ages, 2016 29
  • Figure 10: 7MM, Diagnosed Prevalent Cases of CD by Severity, Both Sexes, All Ages, 2016 30
  • Figure 11: 7MM, Diagnosed Prevalent Cases of CD with Psoriasis, Ankylosing Spondylitis, and Pyoderma Gangrenosum, Both Sexes, All Ages, 2016 31
  • Figure 12: US and 5EU, Alternate Diagnosed Incident Cases of CD, Both Sexes, All Ages, 2016 32
  • Figure 13: Germany, Spain, Italy, and the UK, Alternate Diagnosed Prevalent Cases of CD, Both Sexes, All Ages, 2016 33
Back to Top